Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Insulinoma-associated Protein 1 (INSM1) Is a Better Marker for the Diagnosis and Prognosis Estimation of Small Cell Lung Carcinoma Than Neuroendocrine Phenotype Markers Such as Chromogranin A, Synaptophysin, and CD56.
Sakakibara R, Kobayashi M, Takahashi N, Inamura K, Ninomiya H, Wakejima R, Kitazono S, Yanagitani N, Horiike A, Ichinose J, Matsuura Y, Nakao M, Mun M, Nishio M, Okumura S, Motoi N, Ito T, Miyazaki Y, Inase N, Ishikawa Y. Sakakibara R, et al. Among authors: inase n. Am J Surg Pathol. 2020 Jun;44(6):757-764. doi: 10.1097/PAS.0000000000001444. Am J Surg Pathol. 2020. PMID: 32118626
EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer.
Sakakibara R, Inamura K, Tambo Y, Ninomiya H, Kitazono S, Yanagitani N, Horiike A, Ohyanagi F, Matsuura Y, Nakao M, Mun M, Okumura S, Inase N, Nishio M, Motoi N, Ishikawa Y. Sakakibara R, et al. Among authors: inase n. Clin Lung Cancer. 2017 Sep;18(5):527-534.e1. doi: 10.1016/j.cllc.2016.12.002. Epub 2016 Dec 22. Clin Lung Cancer. 2017. PMID: 28111119
High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.
Ariyasu R, Nishikawa S, Uchibori K, Oh-Hara T, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Kitazono S, Yanagitani N, Horiike A, Inase N, Kasahara K, Nishio M, Katayama R. Ariyasu R, et al. Among authors: inase n. Lung Cancer. 2018 Mar;117:1-6. doi: 10.1016/j.lungcan.2017.12.018. Epub 2018 Jan 4. Lung Cancer. 2018. PMID: 29496249
Treatment and monitoring of hypersensitivity pneumonitis.
Miyazaki Y, Tsutsui T, Inase N. Miyazaki Y, et al. Among authors: inase n. Expert Rev Clin Immunol. 2016 Sep;12(9):953-62. doi: 10.1080/1744666X.2016.1182426. Epub 2016 May 17. Expert Rev Clin Immunol. 2016. PMID: 27117830 Review.
A phase II feasibility study of carboplatin and nab-paclitaxel for advanced non-small cell lung cancer patients with interstitial lung disease (YLOG0114).
Sakashita H, Uchibori K, Jin Y, Tsutsui T, Honda T, Sakakibara R, Mitsumura T, Nukui Y, Shirai T, Masuo M, Suhara K, Furusawa H, Yamashita T, Ohba T, Saito K, Takagiwa J, Miyashita Y, Inase N, Miyazaki Y. Sakashita H, et al. Among authors: inase n. Thorac Cancer. 2022 May;13(9):1267-1275. doi: 10.1111/1759-7714.14376. Epub 2022 Mar 23. Thorac Cancer. 2022. PMID: 35322551 Free PMC article. Clinical Trial.
192 results